Washing kidneys to stop hidden virus: new trial aims to make transplants safer
NCT ID NCT07488481
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-stage trial tests whether treating a donor kidney with a drug called SYN002 before transplant can safely reduce the risk of passing cytomegalovirus (CMV) to the recipient. About 12 adults waiting for a kidney transplant will receive a treated organ. The main goal is to see if the kidney works well after transplant and if the treatment is safe.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CYTOMEGALOVIRUS (CMV) INFECTION are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
University Health Network, Toronto General Hospital, Ajmera Transplant Centre
Toronto, Ontario, M5G 2N2, Canada
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new drug work safely in patients with kidney failure?
- Can an antibody boost help transplant patients beat CMV faster?
- What does life feel like for children with a rare birth defect? a new study asks
- AI therapy coach aims to ease distress in seriously ill seniors
- A simple stretch during dialysis might soothe restless legs
- A regenerative graft could rethink dialysis access